These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36351986)

  • 1. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort.
    Freise NF; Gliga S; Fischer J; Lübke N; Lutterbeck M; Schöler M; Bölke E; Orth HM; Feldt T; Roemmele C; Wilke D; Schneider J; Wille K; Hohmann C; Strauss R; Hower M; Ruf A; Schubert J; Isberner N; Stecher M; Pilgram L; Vehreschild JJ; ; Hanses F; Luedde T; Jensen B
    Sci Rep; 2022 Nov; 12(1):19035. PubMed ID: 36351986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study.
    Rogers R; Shehadeh F; Mylona EK; Rich J; Neill M; Touzard-Romo F; Geffert S; Larkin J; Bailey JA; Lu S; Sweeney J; Mylonakis E
    Clin Infect Dis; 2021 Jul; 73(1):e208-e214. PubMed ID: 33038227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19.
    Arnold Egloff SA; Junglen A; Restivo JS; Wongskhaluang M; Martin C; Doshi P; Schlauch D; Fromell G; Sears LE; Correll M; Burris HA; LeMaistre CF
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
    Mendoza RP; Fyke W; Daniel D; Gabutan E; Das B; Bajaj H; Easy M; Vasileva A; Colbourn R; Alawad M; Dehghani A; Lin B; Emechebe D; Patel P; Jabbar A; Nikolov DB; Giovaniello D; Kang S; Tatem L; Bromberg K; Augenbraun M; Premsrirut P; Libien J; Norin AJ
    Hum Immunol; 2021 Apr; 82(4):255-263. PubMed ID: 33640208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry.
    De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M;
    Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease severity in hospitalized COVID-19 patients: comparing routine surveillance with cohort data from the LEOSS study in 2020 in Germany.
    Koppe U; Schilling J; Stecher M; Rüthrich MM; Marquis A; Diercke M; Haselberger M; Koll CEM; Niebank M; Ruehe B; Borgmann S; Grabenhenrich L; Hellwig K; Pilgram L; Spinner CD; Paerisch T;
    BMC Infect Dis; 2023 Feb; 23(1):89. PubMed ID: 36765274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)".
    Jakob CEM; Borgmann S; Duygu F; Behrends U; Hower M; Merle U; Friedrichs A; Tometten L; Hanses F; Jung N; Rieg S; Wille K; Grüner B; Klinker H; Gersbacher-Runge N; Hellwig K; Eberwein L; Dolff S; Rauschning D; von Bergwelt-Baildon M; Lanznaster J; Strauß R; Trauth J; de With K; Ruethrich M; Lueck C; Nattermann J; Tscharntke L; Pilgram L; Fuhrmann S; Classen A; Stecher M; Schons M; Spinner C; Vehreschild JJ
    Infection; 2021 Feb; 49(1):63-73. PubMed ID: 33001409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
    JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study.
    Hoepler WP; Weidner L; Traugott MT; Neuhold S; Meyer EL; Zoufaly A; Seitz T; Kitzberger R; Baumgartner S; Pawelka E; Karolyi M; Grieb A; Hind J; Laferl H; Friese E; Wenisch C; Aberle SW; Aberle JH; Weseslindtner L; Jungbauer C
    Infect Dis (Lond); 2021 Nov; 53(11):820-829. PubMed ID: 34128763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
    Tang J; Grubbs G; Lee Y; Golding H; Khurana S
    Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
    Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
    Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague.
    Bohoněk M; Řezáč D; Holub M
    Cas Lek Cesk; 2020; 159(5):175-180. PubMed ID: 33297703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.
    Khan TNS; Mukry SN; Masood S; Meraj L; Devrajani BR; Akram J; Fatima N; Maqsood S; Mahesar A; Siddiqui R; Ishaque S; Afzal MB; Mukhtar S; Ahmed S; Naz A; Shamsi TS
    BMC Infect Dis; 2021 Sep; 21(1):1014. PubMed ID: 34579646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.
    Rüthrich MM; Giessen-Jung C; Borgmann S; Classen AY; Dolff S; Grüner B; Hanses F; Isberner N; Köhler P; Lanznaster J; Merle U; Nadalin S; Piepel C; Schneider J; Schons M; Strauss R; Tometten L; Vehreschild JJ; von Lilienfeld-Toal M; Beutel G; Wille K;
    Ann Hematol; 2021 Feb; 100(2):383-393. PubMed ID: 33159569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.